These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 11693316)

  • 21. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
    Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
    Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
    Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.
    Blount PL; Galipeau PC; Sanchez CA; Neshat K; Levine DS; Yin J; Suzuki H; Abraham JM; Meltzer SJ; Reid BJ
    Cancer Res; 1994 May; 54(9):2292-5. PubMed ID: 8162566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study.
    Hadjinicolaou AV; van Munster SN; Achilleos A; Santiago Garcia J; Killcoyne S; Ragunath K; Bergman JJGHM; Fitzgerald RC; di Pietro M
    EBioMedicine; 2020 Jun; 56():102765. PubMed ID: 32460165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
    Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.
    Maley CC; Galipeau PC; Li X; Sanchez CA; Paulson TG; Blount PL; Reid BJ
    Cancer Res; 2004 Oct; 64(20):7629-33. PubMed ID: 15492292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.
    Wong DJ; Paulson TG; Prevo LJ; Galipeau PC; Longton G; Blount PL; Reid BJ
    Cancer Res; 2001 Nov; 61(22):8284-9. PubMed ID: 11719461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Walch A; Mueller J; Höfler H; Werner M
    J Natl Cancer Inst; 2000 Jul; 92(14):1182-3. PubMed ID: 10904093
    [No Abstract]   [Full Text] [Related]  

  • 35. Significance of Crypt Atypia in Barrett's Esophagus: A Clinical, Molecular, and Outcome Study.
    Wang HH; Patil DT; Paulson TG; Grady WM; Odze RD
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):741-748.e2. PubMed ID: 37879518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.
    Chao DL; Sanchez CA; Galipeau PC; Blount PL; Paulson TG; Cowan DS; Ayub K; Odze RD; Rabinovitch PS; Reid BJ
    Clin Cancer Res; 2008 Nov; 14(21):6988-95. PubMed ID: 18980994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci.
    Hage M; Siersema PD; Vissers KJ; Dinjens WN; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    Int J Cancer; 2006 Jan; 118(1):155-60. PubMed ID: 16032707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma.
    Blount PL; Ramel S; Raskind WH; Haggitt RC; Sanchez CA; Dean PJ; Rabinovitch PS; Reid BJ
    Cancer Res; 1991 Oct; 51(20):5482-6. PubMed ID: 1680552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
    Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
    J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.